Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
JPBI
Special Issues
Feature Papers to Celebrate the Inaugural Issue of Journal of...
share announcement

Feature Papers to Celebrate the Inaugural Issue of Journal of Pharmaceutical and BioTech Industry

A special issue of Journal of Pharmaceutical and BioTech Industry (ISSN 2813-9380).

Deadline for manuscript submissions: 30 September 2025 | Viewed by 1943

Special Issue Editor

Prof. Dr. Fernando Albericio

E-Mail Website
Guest Editor
1. School of Chemistry and Physics, University of KwaZulu-Natal, Durban, South Africa
2. Department of Organic Chemistry, University of Barcelona, Barcelona, Spain
Interests: antimicrobial peptides; solid-phase chemistry; combinatorial chemistry; drug delivery systems; peptide drug conjugates; orthogonal chemistry; drug discovery; biomaterials
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

The pharmaceutical and biotechnology industry continues to be one of the most important industry sectors for various reasons. It is essential for global health and the well-being of the public, as well as for the success of many countries’ economies. The discovery, development, manufacturing, and supply of pharmaceutical products, i.e., bench to bed, is one of the most versatile, multi-faceted, and innovative human endeavors. The aim of this Special Issue, titled "Feature Papers to Celebrate the Inaugural Issue of Journal of Pharmaceutical and BioTech Industry", is to highlight cutting-edge studies in all aspects of the discovery, development, delivery, and manufacturing of drugs. We invite all authors to contribute original research articles and timely review articles. This Special Issue of the Journal of Pharmaceutical and BioTech Industry is also expected to showcase contributions from scientists, engineers, and formulators in academia, industry, and regulatory agencies. Besides studies conducted by a single university, laboratory, or company, collaborative studies performed by multiple constituencies, e.g., academia–industry, academia–regulator, or academia–industry–regulator, are especially welcome, as are inter- or multi-disciplinary studies. The authors should consult the aims and scope of the Journal of Pharmaceutical and BioTech Industry for a more detailed scope of the journal.

* We dedicate this Special Issue to the memory of our Founding Editor-in-Chief, Prof. Dr. Ecevit Bilgili, who initiated this Special Issue but sadly passed away during its preparation.

Prof. Dr. Fernando Albericio
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Pharmaceutical and BioTech Industry is an international peer-reviewed open access quarterly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1000 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • drug discovery
  • drug development
  • drug delivery
  • drug manufacturing
  • pharmaceutical and biotech industry
  • pharmaceutics
  • regulatory sciences

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review

16 pages, 2180 KiB  
Article
A Precipitation-Based Process to Generate a Solid Formulation of a Therapeutic Monoclonal Antibody: An Alternative to Lyophilization
by Athanas A. Koynov, Wei Lin, Jameson R. Bothe, Luke Schenck, Bibek Parajuli, Zhao Li, Richard Ruzanski, Natalie Hoffman, Derek Frank and Zachary VanAernum
J. Pharm. BioTech Ind. 2025, 2(1), 2; https://doi.org/10.3390/jpbi2010002 - 31 Jan 2025
Viewed by 335
Abstract
Lyophilization, or freeze-drying, is the default technique for the manufacture of solid-state formulations of therapeutic proteins. This established method offers several advantages, including improved product stability by minimizing chemical degradation, reduced storage requirements through water removal, and elimination of cold chain dependence. However, [...] Read more.
Lyophilization, or freeze-drying, is the default technique for the manufacture of solid-state formulations of therapeutic proteins. This established method offers several advantages, including improved product stability by minimizing chemical degradation, reduced storage requirements through water removal, and elimination of cold chain dependence. However, the lyophilization process itself presents limitations. It is a lengthy, batch-based operation, potentially leading to product inconsistencies and high manufacturing costs. Additionally, some proteins are susceptible to structural alterations during the freezing step, impacting their biological activity. This paper presents an alternative approach based on the co-precipitation of protein and excipients using an organic solvent. We explore the impact of various processing parameters on the viability of the formulation. We also provide an extensive characterization of proteins reconstituted from precipitated formulations and compare protein stability in solution and in lyophilized and precipitated solid formulations under long-term, accelerated, and stressed storage conditions. Full article
(This article belongs to the Special Issue Feature Papers to Celebrate the Inaugural Issue of Journal of Pharmaceutical and BioTech Industry)
►▼ Show Figures

Graphical abstract

Review

Jump to: Research

34 pages, 1227 KiB  
Review
Non-Traditional Natural Stabilizers in Drug Nanosuspensions
by Simay Ozsoysal and Ecevit Bilgili
J. Pharm. BioTech Ind. 2024, 1(1), 38-71; https://doi.org/10.3390/jpbi1010005 - 13 Dec 2024
Viewed by 1121
Abstract
Poor solubility of many drugs, with ensuing low bioavailability, is a big challenge in pharmaceutical development. Nanosuspensions have emerged as a platform approach for long-acting injectables and solid dosages that enhance drug bioavailability. Despite improvements in nanosuspension preparation methods, ensuring nanosuspension stability remains [...] Read more.
Poor solubility of many drugs, with ensuing low bioavailability, is a big challenge in pharmaceutical development. Nanosuspensions have emerged as a platform approach for long-acting injectables and solid dosages that enhance drug bioavailability. Despite improvements in nanosuspension preparation methods, ensuring nanosuspension stability remains a critical issue. Conventionally, synthetic and semi-synthetic polymers and surfactants are used in nanosuspension formulations. However, no polymer or surfactant group is universally applicable to all drugs. This fact, as well as their toxicity and side effects, especially if used in excess, have sparked the interest of researchers in the search for novel, natural stabilizers. The objective of this paper is to provide a comprehensive analysis of non-traditional natural stabilizers reported in the literature published over the last decade. First, physical stability and stabilization mechanisms are briefly reviewed. Then, various classes of non-traditional natural stabilizers are introduced, with particular emphasis on their stabilization potential, safety, and pharmaceutical acceptability. Wherever data were available, their performance was compared with the traditional stabilizers. Furthermore, the benefits and limitations of using these stabilizers are examined, concluding with future prospects. This review is expected to serve as a valuable guide for researchers and formulators, offering insights into non-traditional natural stabilizers in drug nanosuspension formulations. Full article
(This article belongs to the Special Issue Feature Papers to Celebrate the Inaugural Issue of Journal of Pharmaceutical and BioTech Industry)
►▼ Show Figures

Graphical abstract

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop